Use of nesiritide in the management algorithm of acute decompensated heart failure

0Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Acute decompensated heart failure (ADHF) is an emerging component of heart failure that is incompletely understood, lacks clear pathophysiologic mechanisms, is associated with worrisome outcomes, and is confounded by only minimally effective treatment options. Currently, treatment is targeted toward abnormal hemodynamics and includes diuretics, vasodilators, and inotropes. Nesiritide (B-type natriuretic peptide), represents a novel therapeutic option for ADHF that lowers elevated filling pressures and improves dyspnea. However, the risk/benefit ratio represents an unresolved issue, as important questions persist regarding drug-related morbidity and mortality. More research is needed to address safety, identify the ideal clinical scenario, and to resolve the absence or presence of drug associated risks. © 2008 Springer-Verlag London.

Cite

CITATION STYLE

APA

Yancy, C. W. (2008). Use of nesiritide in the management algorithm of acute decompensated heart failure. In Acute Heart Failure (pp. 551–563). Springer London. https://doi.org/10.1007/978-1-84628-782-4_51

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free